



## **National Pharmaceutical Association Foundation**

**CALL FOR ABSTRACTS**

**Submission Deadline:**

**April 22<sup>nd</sup>, 2017**

**National Pharmaceutical Association/Student National  
Pharmaceutical Association National Convention**

**July 28- 31, 2017**

**Planet Hollywood Las Vegas**



The National Pharmaceutical Association (NPhA) Foundation invites you to submit abstracts for the poster presentation session at the 2017 National Meeting in Las Vegas, NV. NPhA is dedicated to representing the views and ideals of minority pharmacists on critical issues affecting health care and pharmacy, as well as advancing the standards of pharmaceutical care among all practitioners.

### ABSTRACT SUBMISSION INSTRUCTIONS AND GUIDELINES

Abstracts addressing health disparities and health initiatives impacting minority and disadvantaged patients are strongly encouraged. Selected abstracts will be eligible to present at the poster session during the Exhibit at the 70th Annual National Convention .

Abstracts will only be accepted via electronic submission. **Abstracts that do not conform to official guidelines will not be accepted.**

A presenting author is expected to register to attend the National 2017 Convention to present the poster. Abstracts will not be considered without receipt of an Abstract Submission Form from the author(s).

- **DEADLINE:** All abstracts and submission forms must be received by email ([ruth.awosika@npha.net](mailto:ruth.awosika@npha.net)) no later than **11:59PM Eastern, Saturday April 22<sup>nd</sup>, 2017**. No corrections will be allowed once submitted.
- **ELIGIBILITY:** All abstracts should represent the mission of NPhA /SNPhA and health disparate communities.
- **ACKNOWLEDGEMENT:** All abstracts will receive notification of receipt no later than **2 weeks after submission**. Notification of acceptance will be sent no later than **Friday May 26<sup>th</sup>, 2017**. All notifications will be made via email from [ruth.awosika@npha.net](mailto:ruth.awosika@npha.net).
- **SUBMISSION REQUIREMENTS:** Please submit abstracts via the attached form. Abstracts will not be processed for review if they are not submitted using the form.

### ABSTRACT INSTRUCTIONS

- Maximum of 300 word count (excluding title, authors, section titles, affiliations, and mention of grant support). Define all abbreviations the first time they appear in the abstract.
- Avoid formulas.
- Do not include references or credits.
- Single space all typing; double space between paragraphs/sections.
- To maintain legibility, avoid use of ornate or script fonts. Block fonts like Arial, Calibri or conservative serif types like Times New Roman and Bookman read well. Please submit abstracts with a 12-point font using sans or serif type.

**Figure 1: Sample Fonts (all fonts shown at 12 pt)**

Arial	Times New Roman	Bookman	Calibri
-------	-----------------	---------	---------

- Proofread the abstract carefully before submitting; no corrections will be allowed.
- Submit computer file of abstract. File must be in a PC-compatible format, preferably Microsoft® Word.

**\*\*Abstracts will be peer-reviewed for content, quality, topic applicability, and appropriateness to the mission and purpose of NPhA/SNPhA. Authors may submit more than one abstract, but must do so on separate forms. It is important to note that just because you submit an abstract does not mean that you will be selected to present at the National Meeting.**

Please submit completed forms via email to be received no later than **11:59PM Eastern, Saturday April 22<sup>nd</sup>, 2017** to [ruth.awosika@npha.net](mailto:ruth.awosika@npha.net) (Email subject: NPhA Abstract Submission).

Any questions regarding the abstract submission process should be directed to Dr. Ruth Awosika via email ([ruth.awosika@npha.net](mailto:ruth.awosika@npha.net)) or phone at 310-413-6456.

***ABSTRACTS SUBMITTED VIA FAX WILL NOT BE ACCEPTED***

**See Guidelines & Sample Research and or Clinical Practice/Project Abstracts below:**

**RESEARCH Abstracts must be organized using the following format:**

- **Title** (upper-case letters) maximum 60 characters
- **Author(s)** (upper and lower-case letters) who have significantly contributed to the work; optimal limit 5-10
  - Presenting author must be listed first
  - For each author, include first and second initials and last name. Separate authors with semi-colon
  - Include titles after each person's name, separated with commas  
**Example:** KP Lewis, PharmD, CACP, BCACP, CPP; NV Nickson, MD; SB Levee, PhD
- **Affiliation(s)**
  - List institution(s) where work was performed. Present affiliation information in a new line immediately following author line and include author initials following affiliation  
**Example:**  
KP Lewis, PharmD, CACP, BCACP, CPP; NV Nickson, MD; SB Levee, PhD  
Campbell University (KPL); No Way Around It (NVN, SBL)
- **Purpose** (header in upper-case letters)
  - Explain the importance of the research or activity to include objectives, goals and purpose
- **Design Methods** (header in upper-case letters)
  - Briefly explain the procedure and strategy used to gather the information presented
- **Results/Expected Results** (header in upper-case letters)
  - What did you find when you performed the analysis of the information presented?
- **Discussion/Conclusion** (header in upper-case letters)
  - How does the result address the hypothesis?
  - How do the reported findings contribute to the knowledge in the respective field?
- **Mention of Grant Support** (where applicable)
  - Authors are encouraged to acknowledge grant support for work

## USE OF PICTORIAL AIDS TO IMPROVE ADHERENCE IN LOW LITERACY

KP Lewis, PharmD, CACP, BCACP, CPP

Campbell University College of Pharmacy and Health Sciences; Southern Regional Area Health Education Center

### PURPOSE

Medication adherence and patient education are of utter importance in the management of disease states; an important aspect of medication adherence is health literacy. Conveying information to improve adherence to patients who have low literacy levels is a challenge. This study was conducted to assess the improvements in clinical outcomes, medication adherence and patient satisfaction with the use of a pill box using pictorial aids.

### DESIGN METHODS

Patient literacy level assessed by the library staff and physician, then referred to pharmacy for education on disease states (diabetes, hypertension, hyperlipidemia) and importance of adhering to medications as prescribed. A usual pill box was modified for the patient using pictorial aids. Patient's blood pressure, blood sugar averages will be assessed at baseline and weeks 2, 4, 8, and 12. Patient satisfaction will be assessed at week 12. Medication adherence is assessed via pill counts at each visit.

### RESULTS/EXPECTED RESULTS

Patient's blood pressure and fasting blood sugar was lower at weeks 2 and 4 compared to baseline. It is expected that the patient's blood pressure and blood sugars will remain lower than baseline with continued adherence. It is also expected that the patient will still be using and will be satisfied with the modified pill box at the 12-week period.

### DISCUSSION/CONCLUSION

Modification of "conventional" educational methods and appropriate education can effectively improve a patient's medication adherence. This, in turn, ultimately improves outcomes. This process can hopefully be expanded to others with low health literacy or other literacy issues.

**\*Financial Disclosure Box:** Nothing to disclose

**CLINICAL PRACTICE/PROJECTS** abstracts must be organized using the following format:

- **Title** (upper-case letters) maximum 60 characters
- **Author(s)** (upper and lower-case letters) who have significantly contributed to the work; optimal limit 5-10
  - Presenting author must be listed first
  - For each author, include first and second initials and last name. Separate authors with semi-colon
  - Include titles after each person's name, separated with commas  
**Example:** KP Lewis, PharmD, CACP, BCACP, CPP; NV Nickson, MD; SB Levee, PhD
- **Affiliation(s)**
  - List institution(s) where work was performed. Present affiliation information in a new line immediately following author line and include author initials following affiliation  
**Example:**  
KP Lewis, PharmD, CACP, BCACP, CPP; NV Nickson, MD; SB Levee, PhD  
Campbell University (KPL); No Way Around It (NVN, SBL)
- **Purpose** (header in upper-case letters)
  - Explain the importance of the research or activity to include objectives, goals and purpose
- **Project Description** (header in upper-case letters)
  - Describe the problem/issue to be considered, the key factors underlying the issue
  - Give information on the Best Practice Guidelines used to address the problem/issue and protocols used to incorporate these guidelines into practice (for clinical practice submission)
  - Implications and recommendations for clinical practice moving forward (for clinical practice submission)
  - Give outcomes associated with your project/event
- **Mention of Grant Support** (where applicable)
  - Authors are encouraged to acknowledge grant support for work

## IMPLEMENTATION OF A PHARMACY STUDENT-HIGH SCHOOL STUDENT MENTOR PROGRAM

HN Knox, PharmD Candidate; PO Weekly, PharmD Candidate; TP Yew, PharmD  
Campbell University College of Pharmacy and Health Sciences (HNK, TPY); Buies Creek High School (POW)

### PURPOSE

To establish a mentor program between current pharmacy students and those interested in the career of pharmacy.

### PROGRAM DESCRIPTION

The program was created to inspire and encourage young men and women to achieve their goals and pursue a career in pharmacy. Pharmacy students and high school students signed up to participate in the program. The number of participants was limited to 15 for this pilot program. Activities were planned throughout the year in order to allow the mentors and mentees to interact in various capacities. Activities included: shadow days in pharmacy classes, career awareness day and tutoring. Once a quarter, student topic discussions were led by the pharmacy students to increase students' skills in communicating and collaborating. Fifteen high school young men and women signed up to participate, along with 20 pharmacy students (5 students had 2 mentors). The pilot is set to end May 2013. Both mentor and mentee satisfaction with the program and suggestions will be obtained.

### PROJECT OUTCOMES

To be presented at the National Meeting in New Orleans, LA.

**Note:** For presentation projects that do not report data, please give a full description of the activity and its implications and results.

**FINANCIAL DISCLOSURE BOX\*:** North Carolina Diversity grant recipient

**Abstract Evaluation Criteria**

Abstracts should be developed to meet the following technical review criteria:

1. Importance and relevance of topic.
2. Adherence to the National Pharmaceutical Association's mission to serve the underserved communities.
3. Innovation and contribution to knowledge base
4. Clarity and completeness-made up of the following: overall quality, purpose and objective, theoretical and/or applied focus, research/activity methods, findings, and potential practical application.
5. Well organized and clearly written.
6. Potential contributions of the study to science/society.
7. Research design:
  - a. Explicit background information
  - b. Sufficient information about the data collection and analysis procedures (if applicable)
8. Results:
  - a. Discussion of empirical studies, or in the case where the study has not yet been carried out, details of any predictions about the expected direction of the findings.
  - b. Results likely to be of value to the field

**AWARDS INFORMATION**

The NPhA Foundation offers awards for the hard work and dedication of deserving SNPhA members.

**STUDENT** presenters are eligible to receive the Poster Presentation Award/Recognition. Posters evaluated and presented may be eligible to receive:

- 1<sup>st</sup> place: \$500
- 2<sup>nd</sup> place: \$250
- 3<sup>rd</sup> place: \$100

Award determination will be based on evaluations of the specified judges at the poster sessions at the National Convention.





**National Pharmaceutical Association Abstract Submission Form**

**Presenter Information**

Name and Degree(s) \_\_\_\_\_

Organization \_\_\_\_\_

Job Title \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Postal Code \_\_\_\_\_

Email Address \_\_\_\_\_

Telephone \_\_\_\_\_ Fax Number \_\_\_\_\_

Are you currently a:     STUDENT PHARMACIST                       PRACTICING/RETIRED PHARMACIST  
*(CIRCLE ONE)*

**Abstract Type**

Which category are you submitting your abstract for consideration?

RESEARCH

CLINICAL PRACTICE/PROJECT

**Abstract Title**

\_\_\_\_\_  
 \_\_\_\_\_

**Author(s) and Affiliation(s)**

\_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

Please submit the abstract (no more than 300 words) typed or printed to ensure an accurate listing in the program. Abstract examples are found on pages 4 and 6 of this packet.

\*Financial Disclosure Box:

**FINANCIAL DISCLOSURE POLICY**

The National Pharmaceutical Association is required to disclose to our attendees any significant financial interest or arrangement with any organization or institution whose products or services are being discussed in a session. Financial interest or relationship can include: contracts; grants; employment; consultant fees; ownership or partnership; stock or bond holdings; and other remuneration (for example honoraria and travel expenses).

Having a significant financial interest does NOT prevent an individual from presenting at a session nor does it prevent us from accrediting the activity for continuing education credits. However, the existence of the relationship must be known to the audience prior to the session, so that the audience may form their own judgments about the presentation.

Any such financial interest or arrangement will be disclosed to our National Meeting participants in the Conference Program or through other appropriate means.

**FINANCIAL DISCLOSURE STATEMENT**

I have read the National Pharmaceutical Association’s policy on full disclosure and I declare that (initial):  
 \_\_\_\_\_ I DO NOT have any significant financial interest, arrangement, or affiliation with any organization or institution whose products or services are being discussed in this session.

\_\_\_\_\_ I HAVE a significant financial interest, arrangement, or affiliation with an organization or institution whose products or services are being discussed in this session. I understand that I must disclose this information to the participants who attend my session. PLEASE COMPLETE THE NEXT TWO STEPS:

1. Below, list the financial interest, arrangements or affiliations as well as the nature of the relationship with each institution, such as contracts, grants, employment, consultant fees, ownership or partnership, stock or bond holdings, and other remuneration (for example honoraria and travel expenses).
2. On the Abstract Submission Form within the abstract box, you must fill in the Financial Disclosure Box\* with the name of the Organization/Institution whose products or services are being discussed.

\_\_\_\_\_  
**Name of presenter (please print or type)**                      **Signature of presenter**                      **Date**

ORGANIZATION/INSTITUTION	RELATIONSHIP (grants, employment, etc.)

The financial disclosure statement **MUST** be filled out completely and signed before any abstract will be reviewed. Incomplete or illegible forms will be returned and not accepted.

**Abstract Submission Checklist**

- Abstract prepared according to instructions
  - Does not exceed 300 words
  - Abstract is single spaced with double spacing between paragraphs.
  - 12-point font used
  - Arial, Calibri, Times New Roman or Bookman font used
  - Abstract submitted in PC-compatible format, preferably Microsoft® Word
  - DO NOT send an image of your abstract.
  
- Abstract submission form (one per abstract) fully completed.
  
- Financial Disclosure Form completed and signed
  
- Registration Complete for National Convention